Huangpu leads high-quality development with innovation

A delegation of media agencies walked along Chuangxin Avenue and visited the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) National Institute for Nanotechnology Innovation, at the China-Singapore Wisdom Park on Feb 20, to learn about how technological transformation is accelerating Huangpu's high-quality development.

On Feb 21, the delegation visited enterprises and research institutes, such as Paizhen Biology and the GBA National Technology Innovation Center, to uncover how the innovation benefits Huangpu.

Located in the Science and Technology Enterprise Accelerator Park in Huangpu district, Guangzhou Moxi Technology has been promoting the basic research of nano-three-dimensional graphene to achieve high-quality development and self-reliance.

Chen Jianhao, founder and chief scientist of Guangzhou Moxi Technology, expressed that after three years of hard research and development, the company stands out internationally in this field, and has created new technology for the mass production of three-dimensional stable graphene materials.

Currently, this technology has a wide range of commercial applications and broad future application prospects.

Paizhen Biology, which has been devoted to making gene therapy drugs affordable for the general public since its establishment, has been researching the basis of delivery carriers and scaling technology in Huangpu for more than eight years.

At present, PackGene Biotech has built the largest AAV (viral carrier) production base in Asia, accounting for more than 30 percent of the domestic market share, and reducing the cost of AAV by half compared to its competitors.

Talents, science, and technology are things that PackGene has always held in high regard. The company has set up a research and development team of more than 50 people and insists on innovating and breaking through core technology bottlenecks. In addition, PackGene invests 20 to 30 percent of its operating income every year, according to Zhang Chao, general manager of PackGene Biotech.

To date, there are less than 20 companies in the world that can produce clinical-grade AAV carriers, and PackGene Biotech is one of them.

Since 2019, two-thirds of the high-level innovation research institutes certified by Guangdong province have settled in Huangpu. 

Among them, 26 new provincial R&D institutions account for 42 percent of Guangzhou's total. Meanwhile, eight high-level provincial innovation research institutes account for two-thirds of the province's total. 

In the future, Huangpu will continue to use innovation as a driving force toward high-quality development.

China-Singapore Wisdom Park.